Pipeline · Bill → Law
Step 1
Introduced
May 25, 2021
Step 2
Referred
May 26, 2021
E&C
Step 3
Committee
Nov 17, 2021
Reported out
Step 4
House floor
Step 5
Senate
Dec 16, 2021
Passed Senate
Step 6
Resolve Changes
Step 7
Signed
Dec 23, 2021
SummaryCRS Summary
This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions. The Department of Health and Human Services (HHS) shall award grants to eligible entities for scientific research utilizing data from expanded access to investigational ALS treatments for individuals who are not otherwise eligible for clinical trials. The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other rare neurodegenerative diseases. HHS shall also establish the Pu...
Similar Bills · 1 matches
| Bill | Text overlap | Status |
|---|---|---|
| S. 1813— Accelerating Access to Critical Therapies for ALS Act | 85% | INCORPORATED |
Roll Call Votes · 1
Timeline · 22 actions
Dec 23, 2021
Presented to President.
Dec 23, 2021
Signed by President.
Dec 23, 2021
Became Public Law No: 117-79.
Dec 17, 2021
Message on Senate action sent to the House.
Dec 16, 2021
Passed Senate without amendment by Voice Vote.
Dec 9, 2021
Received in the Senate, read twice.
Dec 8, 2021
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-207.
Dec 8, 2021
Placed on the Union Calendar, Calendar No. 148.
Dec 8, 2021
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Dec 8, 2021
Considered under suspension of the rules.
Dec 8, 2021
DEBATE - The House proceeded with forty minutes of debate on H.R. 3537.
Dec 8, 2021
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Dec 8, 2021
Considered as unfinished business.
Dec 8, 2021
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 423 - 3 (Roll no. 415).ROLL CALLpass
Dec 8, 2021
Motion to reconsider laid on the table Agreed to without objection.
Nov 17, 2021
Committee Consideration and Mark-up Session Held.
Nov 17, 2021
Ordered to be Reported (Amended) by Voice Vote.
Nov 4, 2021
Subcommittee Consideration and Mark-up Session Held.
Nov 4, 2021
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
May 26, 2021
Referred to the Subcommittee on Health.
May 25, 2021
Introduced in House
May 25, 2021
Referred to the House Committee on Energy and Commerce.